Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anabel Jiménez-Millán"'
Autor:
María Dolores García de Lucas, Irene Caballero, José Carlos Fernández-García, Manuel Domínguez-Rodríguez, Paloma Moreno-Moreno, Anabel Jiménez-Millán, Manuel Botana-López, Beatriz Avilés, Juan Francisco Merino-Torres, Alfonso Soto, Cristina Tejera, Cristóbal Morales
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectivesSemaglutide is a glucagon-like peptide 1 receptor agonist that improves glycemic control and achieves weight loss in type 2 diabetes (T2D) patients. Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with chron
Externí odkaz:
https://doaj.org/article/4a72eecf0d654cfd8ea5ada9f4136d81
Autor:
Beatriz Aviles, Anabel Jiménez Millán, Luis Perez Belmonte, María Dolores García de Lucas, Francisco Rivas Ruiz
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Semaglutide has shown safety and efficacy in type 2 diabetic patients (DM2) in extensive clinical studies including patients until eGFR>15ml/min/1.73m2. Our aims are to analyse the changes in metabolic and renal parameters in chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3eb6b62463244c1634554cf8e94c07c9
https://doi.org/10.1093/ndt/gfab094.002
https://doi.org/10.1093/ndt/gfab094.002